Takeda A, Shimada H, Nakajima K, Imaseki H, Suzuki T, Asano T, Ochiai T, Isono K
Second Department of Surgery, School of Medicine, Chiba University, Japan.
Eur J Surg. 2001 Jan;167(1):50-3. doi: 10.1080/110241501750069828.
To investigate the clinical use of p53 autoantibodies as a marker in the postoperative monitoring of colorectal cancer.
Retrospective study.
Teaching hospital, Japan.
40 patients with colorectal cancer who had p53 autoantibodies in their serum preoperatively.
Serial assay of p53 autoantibodies by ELISA before and after resection.
Interpretation by a qualitative analysis.
A significant correlation was observed between curability by surgical resection and postoperative disappearance of p53 autoantibodies. Twenty-seven (96%) of 28 patients, who had p53 autoantibodies and whose cancer was completely removed, had no such antibodies after resection and no recurrence after 7 to 26 months.
Postoperative assays of p53 autoantibodies are potentially useful for predicting recurrence of colorectal cancer in patients who have p53 autoantibodies preoperatively.
研究p53自身抗体作为标志物在结直肠癌术后监测中的临床应用。
回顾性研究。
日本教学医院。
40例术前血清中存在p53自身抗体的结直肠癌患者。
采用酶联免疫吸附测定法(ELISA)在切除前后对p53自身抗体进行连续检测。
通过定性分析进行解读。
观察到手术切除的治愈率与术后p53自身抗体消失之间存在显著相关性。28例存在p53自身抗体且癌症被完全切除的患者中,有27例(96%)在切除后无此类抗体,且在7至26个月后无复发。
对于术前存在p53自身抗体的患者,术后检测p53自身抗体可能有助于预测结直肠癌的复发。